Lack of Epistatic Interaction of SNCA with APOE in Synucleinopathies
Prabhjyot Saini,Eric Yu,Mehrdad A Estiar,Lynne Krohn,Kheireddin Mufti,Uladzislau Rudakou,Jennifer A Ruskey,Farnaz Asayesh,Sandra B Laurent,Dan Spiegelman,Isabelle Arnulf,Jacques Y Montplaisir,Jean-Francois Gagnon,Alex Desautels,Yves Dauvilliers,Gian Luigi Gigli,Mariarosaria Valente,Francesco Janes,Andrea Bernardini,Karel Sonka,David Kemlink,Wolfgang Oertel,Karri Kaivola,Annette Janzen,Giuseppe Plazzi,Elena Antelmi,Francesco Biscarini,Michela Figorilli,Monica Puligheddu,Brit Mollenhauer,Claudia Trenkwalder,Friederike Sixel-Doring,Valerie Cochen De Cock,Christelle Charley Monaca,Anna Heidbreder,Luigi Ferini-Strambi,Femke Dijkstra,Mineke Viaene,Beatriz Abril,Bradley F Boeve,Ronald B Postuma,Guy A Rouleau,Victoria Anselmi,Abubaker Ibrahim,Ambra Stefani,Birgit Hogl,Michele T M Hu,Sonja W Scholz,Ziv Gan-Or
DOI: https://doi.org/10.1101/2024.08.12.24311821
2024-08-22
Abstract:Two recent studies suggested that the APOE ε4 haplotype was associated with increased α-synuclein pathology in cell and mouse models. Genetic variants in the SNCA region have strong association with Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), and idiopathic REM Sleep Behavior Disorder (iRBD), while APOE is a genetic risk determinant for only DLB. To determine if genetic-level interactions between SNCA and APOE exists that can explain the protein-level association, we investigated the genotypic interaction of APOE and SNCA in cohorts of PD, DLB, and iRBD. We analyzed genome-wide association study (GWAS) data from 5,229 PD patients and 5,480 controls, 2,610 DLB patients and 1,920 controls, and 1,055 iRBD patients and 3,667 controls. We used logistic regression interaction models across all 3 cohorts independently between the 1) top GWAS signals of SNCA SNPs and APOE haplotypes, 2) SNP x SNP and 3-way SNP interaction across the entire coding region plus 200kb flanking each gene. No significant interactions were found to be associated with any of the synucleinopathies after correction for multiple testing. Our results do not support a role for genetic interactions between APOE and SNCA across PD, DLB, and iRBD. Since the tested genetic variants affect the expression and function of these proteins, it is likely that any interactions between them does not affect the risk of PD, DLB and iRBD.